Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials - Top-Institutions - MDSpire

Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials

By
Sujata Purja
Yomna Elghanam
Eunyoung Kim
March 24, 2026
0 min

Infection (Springer)

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

#1

Johns Hopkins University

Baltimore, MD
Key Differentiators
- Infectious Diseases
- Clinical Pharmacology
- Epidemiology
#2

Massachusetts General Hospital / Harvard Medical School

Boston, MA
Key Differentiators
- Infectious Diseases
- Pharmacology
- Clinical Trials
#3

University of California, San Francisco (UCSF)

San Francisco, CA
Key Differentiators
- Infectious Diseases
- Clinical Pharmacology
- Microbiology
#4

University of Pennsylvania Perelman School of Medicine

Philadelphia, PA
Key Differentiators
- Infectious Diseases
- Clinical Research
- Pharmacology
#5

Mayo Clinic

Rochester, MN
Key Differentiators
- Infectious Diseases
- Clinical Pharmacology
- Epidemiology

Original Source(s)

Infection (Springer)

Efficacy and safety of vancomycin versus 13 alternatives in MRSA-confirmed skin and soft tissue infections: a meta-analysis of 39 randomized controlled trials

by Sujata Purja, Yomna Elghanam, Eunyoung Kim
March 24, 2026

Related Content

Frontiers In Medicine

Biogenic Caralluma sinaica-derived silver nanoparticles as a synergistic antibacterial and osteoinductive nanoplatform for osteomyelitis management

by Aldayel, Munirah F, Ali, Enas M, Abdallah, Basem M
May 11, 2026

Frontiers In Immunology

Extracellular vesicles in atopic dermatitis: unraveling pathogenic mediators and engineering therapeutic vectors

Frontiers In Immunology

Zone-specific hepatocytes orchestrate the early onset of host immune defenses during Staphylococcus aureus bloodstream infection